Davorin Radosavljević

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

Lowell L. Hart, Renata Ferrarotto, Zoran Andrić et al. · Advances in Therapy · 2020 · 125 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

CISCA (cisplatin vs. carboplatin) meta-analysis: An individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC)

Andrea Ardizzoni, Marcello Tiseo, Luca Boni et al. · Journal of Clinical Oncology · 2006 · 63 citations

Medicine, Oncology, Pharmacology +14

FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study

Thomas Brodowicz, Tudor–Eliade Ciuleanu, Davorin Radosavljević et al. · Annals of Oncology · 2013 · 57 citations

Medicine, Oncology, Pharmacotherapy +13

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

S. Jelić, Labuda Mitrović, Davorin Radosavljević et al. · Lung Cancer · 2001 · 43 citations

Medicine, Oncology, Pharmacology +13

Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning

Mursheda Begum, Grant Lewison, Jacek Jassem et al. · European Journal of Cancer · 2018 · 28 citations · Full text

Medicine, Oncology, Cancer Control +16